FDA Inspection 1180742 — Diazyme Laboratories Inc.

Diazyme Laboratories Inc. — FEI 1000122044

The FDA completed an inspection of Diazyme Laboratories Inc. on Sep 27, 2022 in West Caldwell, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 7 citations were issued during this inspection. Product area: Devices.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 27, 2022
Fiscal Year
2022
Product Type
Devices
Project Area
Compliance: Devices
Location
West Caldwell, NJ (United States)

Citations

IDCFRDescription
1471321 CFR 820.198(a)Lack of or inadequate complaint procedures
235021 CFR 820.25(b)Training - Lack of or inadequate procedures
311521 CFR 820.70(h)Use and removal, Lack of or inadequate procedures
315921 CFR 820.184DHR content
323321 CFR 820.72(a)Calibration, Inspection, etc. Procedures Lack of or Inadequ
326221 CFR 820.250(a)Statistical techniques - Lack of or inadequate procedures
368021 CFR 820.70(a)Process control procedures, Lack of or inadequate procedures

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.